Novo Nordisk A/S, which faces higher demand for its diabetes and weight-loss drugs than it can meet, signed a long-term agreement with Ypsomed Holding AG for the supply of auto-injectors.
Ypsomed is boosting its manufacturing capacity to make large quantities of auto-injectors that Novo can use for various drugs in clinical trials, the Swiss company said in a statement Wednesday. The stock rose as much as 5.2% to a record in early trading.
ncG1vNJzZmivp6x7o7jOqKSbnaKce6S7zGilnq%2BjZK6zwMico56rX2d9c3%2BMaXBmamBku7DCzmagp2Wjqr2xuNhmm56ZnGLEqsDHZrCpq5%2BisqV5xaipZpmlqbxutc2jnJysn6d6sbHNrA%3D%3D